-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 2nd, CDE accepted the clinical trial application for the CD47 monoclonal antibody drug 3D197
3D197 is IMC-002, developed by ImmuneOncia
In March 2021, Silodi introduced IMC-002 from ImmuneOncia
IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47-SIRPα interaction to promote the phagocytosis of cancer cells by macrophages
This application is the first phase I clinical trial of 3D197 in China.
According to a press release from Siddi, this antibody is expected to be used in combination with its PD-L1 product, envolimab, which is subcutaneously injected.
Attachment: Pipeline of Siddi official website